GSK Pharmaceuticals stock: Q4 FY26 profit reached 277.86 crore rupees
NiveshIQ
NSE: GLAXO · Healthcare
Glaxosmithkline Pharmaceuticals Ltd.
₹2,531.40▲ ₹37.10 (+1.49%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on GLAXO. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Glaxosmithkline Pharmaceuticals Ltd.
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) operates across the full pharmaceutical value chain, manufacturing and distributing vaccines, respiratory specialty drugs, and general medicines in India and globally. Its vaccine portfolio includes Shingrix, Havrix, Fluarix Tetra, and Infanrix Hexa, while respiratory offerings feature NUCALA, Trelegy Ellipta, and Seretide, driving a significant share of its revenue. In FY26, the company reported a Q4 net profit of ₹277.86 crore, contributing to a total revenue of ₹3,955 crore and a net income of ₹1,068 crore. Recent developments include a planned analyst meeting on November 4 and mixed technical momentum signals, yet the company remains a key player in the competitive Indian healthcare sector. Analysts maintain a bullish stance with a target
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹3,454 Cr +6.21% | ₹3,749 Cr +8.56% | ₹3,822 Cr +1.93% |
| EBITDA Margin | 26.31% | 31.40% | 34.26% |
| Net Profit | ₹589.96 Cr -3.39% | ₹927.58 Cr +57.23% | ₹1,036 Cr +11.69% |
| EPS | ₹34.83 | ₹54.52 | ₹54.52 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
GlaxoSmithkline Pharmaceuticals Limited (GLAXO.NS) Seasonal returns chart
GlaxoSmithKline Pakistan reports higher quarterly profit for the quarter ended September 30, 2026
🔒
+ 3 more stories about Glaxosmithkline Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹938 Cr, PAT ₹237 Cr, EPS ₹14.00, EBITDA margin 31.5%. Growth context: revenue YoY +16.6%, PAT YoY +15.7%, revenue QoQ -5.7%, PAT QoQ -14.6%.
Product pipeline delivery, domestic demand, export mix, approvals, and margin discipline remain the key forward drivers ...
FY26 (last completed FY): revenue ₹3, 822 Cr, PAT ₹1, 036 Cr, EBITDA margin 34.3%, EPS ₹54.52. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for GLAXO
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track GLAXO alongside your other holdings
Unlock full GLAXO research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Glaxosmithkline Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Glaxosmithkline Pharmaceuticals Ltd.?
Glaxosmithkline Pharmaceuticals Ltd. operates in the Healthcare sector with a market capitalisation of ₹4,422,683.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.